HALO Stock Recent News Halozyme Therapeutics (HALO) 9.12 11/09/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 11:51 AM

Halozyme Therapeutics (HALO) 9.12 $HALO

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 9.12 (-0.03)

Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 9.12 (-0.03)

Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.14 (+0.28), ACAD: 27.69 (-0.25), HALO: 9.12 (-0.03), ISIS: 44.59 (-0.66), NSPH: 0.42 (-0.03)

NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 9.12 (-0.03), NLNK: 32.15 (-2.54), ILMN: 186.35 (-3.52), EXAS: 22.82 (-0.52)

Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 4:54PM CDT
Vertex Pharmaceuticals Inc.'s (VRTX) Kaydeco got favorable vote from PADAC for the treatment of 6 year old and above cystic fibrosis patients with R117H mutation.
MDVN: 112.77 (+7.82), VRTX: 115.93 (-1.36), HALO: 9.12 (-0.03), LGND: 53.94 (-0.97)

Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 12:10PM CDT
Biogen (BIIB) raised its earnings guidance for 2014 once again.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), HALO: 9.12 (-0.03), LGND: 53.94 (-0.97)

Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 112.77 (+7.82), HALO: 9.12 (-0.03), LGND: 53.94 (-0.97)

Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 112.77 (+7.82), OREX: 3.85 (-0.05), HALO: 9.12 (-0.03), LGND: 53.94 (-0.97)

Illumina (ILMN) Looks Strong: Stock Gains 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 7:44AM CDT
Illumina (ILMN) was a big mover last session, as the company saw its shares jump over 9% on the day
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), HALO: 9.12 (-0.03), ILMN: 186.35 (-3.52)

NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 112.77 (+7.82), HALO: 9.12 (-0.03), NLNK: 32.15 (-2.54)

Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), HALO: 9.12 (-0.03), ILMN: 186.35 (-3.52)

Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), VTL: 17.14 (+0.22), ILMN: 186.35 (-3.52)

NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 7:51AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as its shares rose over 7% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), NLNK: 32.15 (-2.54), ILMN: 186.35 (-3.52)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), SNY: 45.69 (-0.17), FOLD: 5.72 (-0.16)

Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency
M2 - Mon Oct 20, 10:35AM CDT
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced the launch and first shipments of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI) in the United States. The treatment was approved by the U.S. Food and Drug Administration (FDA) in September of this year.
HALO: 9.12 (-0.03), BAX: 70.61 (-0.99)

Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 8:39AM CDT
Regeneron Pharmaceuticals, Inc. (REGN) was a big mover last session, as its shares rose nearly 9% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EXAS: 22.82 (-0.52), REGN: 377.84 (+0.90)

Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), EXAS: 22.82 (-0.52)

Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant
PR Newswire - Mon Oct 20, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex® recombinant (hyaluronidase human injection). The FDA approved the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the Patheon® facility in Greenville, North Carolina, for production of finished Hylenex product.
HALO: 9.12 (-0.03)

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), RARE: 44.71 (-0.15), LGND: 53.94 (-0.97)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...